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It is estimated that up to 40% of patients with distantly metastatic melanoma 
develop clinically detectable brain metastases. The prognosis for these patients is very 
poor with an historical median overall survival of approximately 4 months. Targeted 
surgical and radiotherapy-based approaches can improve outcomes in certain patients. 
Over the past decade, the efficacy of systemic treatments for metastatic melanoma has 
improved with the development of anti-CTLA-4 and anti-PD-1-based immunothera-
pies (checkpoint inhibitors) that provide survival benefit. In patients whose melanoma 
expresses a V600 BRAF mutation which activates the MAPK signaling pathway, the 
targeted inhibition of BRAF and MEK also confers survival benefit. These immuno-
modulatory and molecular-targeted approaches have recently been studied in patients 
with melanoma brain metastases to determine efficacy of these approaches in treating 
the brain metastases. Advances in use of chemotherapy, immune checkpoint inhibi-
tors, and BRAF plus MEK inhibitors to treat melanoma brain metastases are discussed.
Keywords: melanoma, brain, metastases, immunotherapy, PD-1, BRAF, 
targeted therapy
1. Introduction
Melanoma arises through the accumulation of genetic aberrations in melanocytes 
which lead to uncontrolled cellular proliferation, resistance to apoptosis, and escape 
from immune surveillance. Melanoma has the potential to metastasize distantly through 
hematologic and lymphatic channels. When distant spread is present, the melanoma is 
classified as stage IV. The American Joint Committee on Cancer (AJCC) eighth edition 
subcategorizes stage IV melanoma into four prognostic subgroups with the worst prog-
nostic group (stage IV M1d) defined by the presence of brain metastases [1]. Melanoma 
is the third most common type of cancer to metastasize to the brain following breast and 
lung cancer. It is estimated that 10–40% of patients with stage IV melanoma eventually 
develop clinically detectable brain metastases [2]. In autopsy series, a high incidence of 
subclinical metastasis is noted as over 50% of patients have brain metastases [2].
2. Management of melanoma brain metastases
Brain metastases can lead to morbidity with the development of seizures, 
cerebral edema, and neurologic symptoms reflective of the part of the brain 
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involved. However, several retrospective analyses have shown that the majority of 
patients with brain metastases are asymptomatic [2]. While metastases can develop 
in any part of the brain, the incidence is not evenly distributed. A study evaluating 
the location of 115 brain metastases showed that 43.5% were located in the frontal 
lobe with only 8.6% in the cerebellum and less than 1% in the hippocampus [3]. 
Similarly, a retrospective single center analysis of 6064 brain metastases in 632 
cancer patients revealed that fewer than 1% of the metastases develop in the hip-
pocampus, while the distribution is highest in the frontal lobe (31.6%) [4].
The prognosis for patients with melanoma metastatic to the brain is very poor 
with an historical median overall survival of approximately 4 months [5]. However, 
prognosis is heterogeneous with a small subset of patients demonstrating greater 
than 3-year survival despite the development of brain metastases. A retrospec-
tive review of 702 patients with melanoma-related brain metastases identified a 
small subset of patients who survived greater than 3 years. These patients were 
largely categorized by the presence of an isolated brain metastasis that was treated 
 surgically [5].
Several retrospective studies have attempted to associate clinical and pathologi-
cal characteristics with the development of brain metastases and with the outcome 
following the development of brain metastasis. A review of clinical features and 
survival outcome in melanoma patients who enrolled in any of 12 clinical trials at 
a single cancer center identified factors prognostic for overall survival [6]. About 
44% of 743 chemotherapy naive melanoma patients developed brain metastases 
with the median overall survival following diagnosis of brain metastases being only 
4.3 months. Age at the time of diagnosis of brain metastases did not predict for sur-
vival outcome. However, the year of diagnosis was prognostic as patients diagnosed 
prior to 1996, the midpoint for inclusion of these patients, had worse survival than 
patients diagnosed after the start of 1996 (4.14 months vs. 5.92 months, p = 0.01). 
While prognosis has improved over time, survival outcomes remain very poor. 
Other prognostic factors included the number of brain metastases with a median 
survival for patients with one to three metastases of 5.92 months as opposed to 
3.52 months for those with more than three brain metastases (HR 1.57, p = 0.001). 
The presence of leptomeningeal involvement conferred an even worse prognosis 
with a median overall survival of only 1.2 months. The development of brain metas-
tases after receiving systemic therapy for extracranial metastases conferred worse 
overall survival compared to developing the brain metastases before or synchronous 
to extracranial metastases (HR 1.78, p < 0.0001). Therefore, in multivariate analy-
sis, the year of diagnosis, number of parenchymal brain metastases, and timing of 
metastases relative to extracranial metastases were significantly associated with 
overall survival. Another retrospective analysis of 49 patients with melanoma 
metastatic to the brain identified as part of a melanoma database collected from 
1998 to 2012 associated survival to the presence or absence of symptoms, number 
of parenchymal brain lesions (one vs. two or more), and response to chemotherapy 
[2]. A multivariate analysis of 89 melanoma patients from a single institution who 
developed brain metastases and who were part of a larger prospectively accrued 
cohort of 900 melanoma patients revealed that the presence of neurologic symp-
toms and extracranial metastases predicted for worsened survival [7].
The modality used to treat brain metastases may reflect prognosis. The median 
survival of 686 patients with melanoma and cerebral metastases treated at the 
Sydney Melanoma Unit between 1985 and 2000 was 8.9, 8.7, 3.4, and 2.1 months, 
respectively, in patients treated with surgery plus postoperative radiotherapy, 
surgery alone, radiotherapy alone, and supportive care alone [8]. While outcomes 
differed in patients receiving surgery and/or radiotherapy compared to best sup-
portive care, the differences may reflect patient selection based on performance 
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status, extent of extracranial metastases, comorbidities, and number, size, and 
location of brain metastases. These features impact the decision to recommend 
surgery or radiation therapy. Furthermore, the size, location, and number of 
metastases impact the ability to perform stereotactic radiosurgery as opposed to 
whole brain radiation therapy.
Overall survival of stage IV melanoma patients also is determined by the effec-
tiveness of systemic therapy. Systemic treatment options have improved over the 
past decade through the development of efficacious immunotherapies and molecu-
larly targeted approaches translating into improvements in survival. Prior to 2011, 
the only two systemic therapies Food and Drug Administration (FDA) approved for 
the treatment of stage IV melanoma were the cytotoxic chemotherapy dacarbazine 
(DTIC) and the cytokine immunotherapy high-dose interleukin-2 (HD-IL2). DTIC 
is an intravenously administered alkylating agent that confers responses in 5–20% 
of stage IV melanoma patients but the responses are largely partial and not durable 
[9]. Treatment with HD-IL2 confers a 16% response rate with 5% of patients devel-
oping complete durable responses [10]. The potential for HD-IL2 to cause capillary 
leak syndrome and cerebral edema limits the ability to use this treatment in patients 
with brain metastases. Neither HD-IL2 nor DTIC have been shown in randomized 
studies to confer overall survival benefit.
Temozolomide is an oral alkylating agent that is metabolized to MTIC the same 
active agent that dacarbazine is metabolized to. Treatment of stage IV melanoma 
patients randomized to treatment with dacarbazine or temozolomide showed 
equivalency in terms of response rate and survival [11]. Temozolomide has better 
penetrance of the central nervous system. A retrospective analysis comparing CNS 
relapse rate in patients who responded to treatment with temozolomide versus 
dacarbazine showed that temozolomide-treated patients had significantly fewer 
CNS relapses [12]. This suggests that temozolomide may prevent development of 
brain metastases in melanoma patients. To assess efficacy of temozolomide in treat-
ing brain metastases in melanoma patients where the metastases did not require 
immediate radiation therapy, a phase II study was performed treating 151 patients 
with temozolomide at dose of 150 milligrams per meter squared (mg/m2) per day 
for 5 days in row every 28 days. Among the 117 patients who did not receive prior 
systemic therapy, the response rate was 7%, while 29% had stabilization of the brain 
metastases. Of the 34 patients who received prior systemic therapy, only 1 patient 
responded and 6 patients developed stable disease in the brain [13]. Therefore, 
while temozolomide demonstrates efficacy in treating melanoma brain metastases, 
the benefit is limited and seen only in a small subset of patients.
An improved mechanistic understanding of the positive and negative regulation 
of the immune system through multiple immune-mediated checkpoints has led to 
the development of more efficacious treatment for stage IV melanoma patients. 
Since 2011, the FDA has approved for treatment of stage IV melanoma an inhibitor 
of the negative regular cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), 
ipilimumab, and two inhibitors of the negative regulator programmed death-1 
(PD-1), nivolumab and pembrolizumab. Ipilimumab is administered intravenously 
at a dose of 3 milligrams per kilogram (mg/kg) every 3 weeks for a total of four doses. 
Nivolumab is administered intravenously at a flat dose of 240 mg intravenously 
every 2 weeks or 480 mg every 4 weeks. Pembrolizumab is administered at a dose of 
200 mg every 3 weeks.
T-cell activation requires binding of the T-cell receptor to an antigen-derived amino 
acid sequence complexed to MHC molecules on antigen presenting cells. For T-cell 
activation, costimulatory interactions are necessary with binding of CD28 on the T-cell 
to B7 on the antigen presenting cell. CTLA-4 is expressed on T-cells and binds to B7 
with higher affinity that CD28 leading to disruption of CD28-B7 interaction thereby 
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dampening the immune response. Ipilimumab is a fully human IgG1 monoclonal 
antibody that binds to CTLA-4 in an inhibitory fashion enhancing T-cell priming and 
decreasing suppressor T-cell activity [14]. A phase III study that randomized previously 
treated stage IV melanoma patients to treatment with ipilimumab alone at a dose of 
3 mg/kg intravenously every 3 weeks for four treatments, a peptide vaccine GP-100 
alone, or the combination of ipilimumab plus the vaccine demonstrated a statistically 
significant improvement in overall survival following ipilimumab treatment [14]. 
The median overall survival was 10.1 months in the ipilimumab group as opposed to 
6.4 months in the gp100 vaccine group (hazard ratio for death of 0.68; p-value < 0.001). 
A pooled analysis of long-term data from 12 phase II and phase III studies encompass-
ing 1861 melanoma patients treated with ipilimumab showed a mean overall survival of 
11.4 months with a survival rate at 3 years of 22% [15].
Nivolumab and pembrolizumab are monoclonal antibodies which inhibit the 
activity of PD-1 leading to increased T-cell activity in the tumor microenvironment 
[16, 17]. PD-1 is expressed on the surface of tumor infiltrating T-cells and binds to 
PD-L1 which is aberrantly expressed on tumor cells leading to functional inhibition 
of the T-cells. Both of the PD-1 inhibitors confer 35–40% response rates and lead to 
significantly improved survival when compared to outcomes following ipilimumab 
treatment [18, 19]. The Keynote-006 phase III study randomized 834 melanoma 
patients to treatment with pembrolizumab or ipilimumab. Median overall survival 
with a median follow-up of 22.9 months was not reached in the pembrolizumab-
treated patients as opposed to 16 months in the ipilimumab-treated patients 
(p = 0.0009). Twenty-four-month overall survival was 55 and 43% in the pembroli-
zumab and ipilimumab groups, respectively (p = 0.0009) [18].
CTLA-4 and PD-1 inhibitors modulate different parts of the immune system, 
and preclinical murine models demonstrate synergistic activity following concur-
rent CTLA-4 and PD-1 blockade [20]. The CheckMate 067 study randomized 945 
advanced melanoma patients to placebo-controlled treatment with ipilimumab 
monotherapy, nivolumab monotherapy, or the combination of ipilimumab plus 
nivolumab [21]. Ipilimumab-treated patients received ipilimumab at dose of 3 mg/kg 
every 3 weeks for a total of four treatments. Nivolumab-treated patients were treated 
with 3 mg/kg nivolumab every 2 weeks. Patients receiving combination therapy were 
treated with ipilimumab at a dose of 3 mg/kg plus nivolumab 1 mg/kg every 3 weeks 
for a total of four doses and then nivolumab alone every 2 weeks at a dose of 3 mg/kg. 
Objective responses were noted in 58, 45, and 19% of combination therapy, nivolumab 
monotherapy- and ipilimumab monotherapy-treated patients, respectively. With 
a minimum 4 year follow-up, the median overall survival was not reached in the 
combination group, was 36.9 months in the nivolumab group, and was 19.9 months in 
the ipilimumab group.
Inhibition individually or in combination of the CTLA-4 and PD-1 checkpoints 
leads to survival benefit for stage IV melanoma patients. However, the initial 
clinical trials excluded patients with untreated brain metastases. To determine the 
antimelanoma efficacy of these immune modulatory approaches in patients with 
untreated brain metastases, clinical trials were developed specifically enrolling 
melanoma patients with untreated brain metastases.
A phase II study of patients with melanoma and untreated brain metastases 
treated with ipilimumab showed intracranial responses in 8 of 51 (16%) of asymp-
tomatic patients who did not need steroids and 1/21 (5%) of patients requiring 
steroids because of perimetastasis edema or neurologic symptoms related to the 
metastases. Median overall survival remained poor being 7 months for patients not 
needing steroids and 3.7 months for patients requiring steroids [22]. The overall 
survival assessment also reflects the time period when the study was conducted 
prior to availability of anti-PD-1 immunotherapies.
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A single center phase II study treated 18 stage IV melanoma patients with at least 
1 untreated or progressive brain metastasis between 5 and 20 mm in diameter and 
without associated neurologic symptoms to treatment with pembolizumab at a dose 
of 10 mg/kg every 2 weeks. Four of the patients (22%) developed a partial response 
in the brain. The responses were durable lasting at least 4 months, and at the time of 
data, cutoff was ongoing in all responders [23].
To determine the intracranial efficacy of combined CTLA-4 and PD-1 blockade, 
a phase II multicenter study, CheckMate 204, treated melanoma patients who had 
at least one measurable nonirradiated brain metastasis with a diameter between 0.5 
and 3 cm and with no associated neurologic symptoms to combined treatment with 
nivolumab and ipilimumab [24]. The primary endpoint was intracranial clinical 
benefit defined as complete or partial response or stable disease at 6 months. Brain 
metastases were felt to not need immediate resection or radiosurgery and patients 
did not receive steroid treatment for at least 10 days prior to treatment initiation. 
The nivolumab was administered at dose of 1 mg/kg and ipilimumab 3 mg/kg every 
3 weeks for four doses followed by single agent nivolumab at dose of 3 mg/kg every 
2 weeks until disease progression or prohibitive toxicity. With a median of 14 month 
follow-up, the rate of intracranial benefit in the 94 patients who were followed 
for at least 6 months was 56% with a 26% complete response rate and 30% partial 
response rate. About 2% of patients had intracranial stable disease that lasted greater 
than 6 months. About 64% of patients did not experience intracranial progression 
of brain metastases 6 months after treatment initiation. The extracranial clinical 
benefit rate was 56% similar to the intracranial rate. As expected, the combination 
immunotherapy treatment led to a 55% rate of high-grade toxicity felt related to the 
immunotherapy. Treatment-related adverse events involving the central nervous 
system were seen in 36% of patients and high-grade CNS toxicity developed in 7% 
of the patients. The most common treatment-related nervous system toxicity of any 
severity was headache affecting 22% of patients with 3% having severe headaches.
Additional evidence that anti-PD-1 immunotherapy has efficacy in treating 
active brain metastases comes from the results of a phase II study conducted at 
four sites in Australia. Melanoma patients with asymptomatic brain metastases 
that did not receive prior localized treatment were randomized to systemic 
therapy with nivolumab or combined nivolumab plus ipilimumab blockade. 
Efficacy was appreciated in both cohorts with intracranial response rates of 20 
and 46% seen in nivolumab alone versus combination therapy-treated patients, 
respectively [25].
Treatment of stage IV melanoma has improved not only through the use 
of immunotherapy but also through the use of molecular-targeted therapies. 
Approximately, 40% of melanomas select for an activating mutation in the protein 
BRAF which is a component of the mitogen-activated protein kinase (MAPK) sig-
naling pathway. The MAPK signaling pathway is a cascade initiated by extracellular 
signals binding to cell membrane receptors activating RAS which then activated 
CRAF and BRAF leading to downstream activation of MEK and ERK. Greater than 
90% of BRAF mutations in melanoma are activating hotspot mutations present at 
position 600 with the most common being a V600E mutation. Activation of BRAF 
leads to melanoma proliferation and survival due to enhanced signaling through 
the MAPK pathway. Three different combinations of BRAF plus MEK inhibitors 
(the BRAF inhibitors dabrafenib, vemurafenib, and encorafenib combined with the 
MEK inhibitors trametinib, cobimetinib, and binimetinib, respectively) are FDA 
approved for the treatment of unresectable melanoma expressing a V600E BRAF 
mutation [26–28]. Randomizing 947 previously untreated patients with unresect-
able melanoma to treatment with dabrafenib plus placebo or dabrafenib plus 
trametinib as part of an international phase III study demonstrated overall survival 
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benefit favoring the dual inhibitor approach [29]. Treatment with dabrafenib 
monotherapy conferred a 53% response rate, while dabrafenib plus trametinib 
treatment led to a 69% response rate. Efficacy is limited by the development of 
resistance with median progression free survival being 8.8 and 11 months for 
patients treated with dabrafenib monotherapy or combination therapy, respectively. 
Two-year overall survival was 42% for patients treated with BRAF inhibition alone 
and improved to 51% for patients treated with concurrent BRAF and MEK inhibi-
tion [29]. Eligibility requirements for the trial required definitive treatment of any 
preexisting brain metastases with confirmed stability of at least 12 weeks. Patients 
with untreated or unstable brain metastases were excluded from enrollment.
To determine the ability of combined BRAF and MEK inhibition to treat pro-
gressive brain metastases in patients with melanoma expressing a V600 BRAF 
mutation, a multicenter international phase II (COMBI-MB) study was performed 
which treated four cohorts with dabrafenib plus trametinib [30]. The four cohorts 
were: A. Patients with melanoma expressing a V600E BRAF mutation and with 
asymptomatic brain metastases, no prior localized therapy to the brain metastases, 
and an ECOG performance status 0 or 1. B. Patients with melanoma expressing a 
V600E BRAF mutation and asymptomatic brain metastases and an ECOG perfor-
mance status 0 or 1 but who received prior localized therapy to the brain metastases. 
C. Patients with melanoma expressing a V600 D/K/R mutation and asymptomatic 
brain metastases and ECOG performance status of 0–1 with or without prior local-
ized treatment of the brain metastases. D. Patients with melanoma expressing a V600 
D.E/K/R BRAF mutation and with symptomatic brain metastasis and an ECOG 
performance status of 0, 1, or 2. The primary endpoint was investigator-assessed 
intracranial response in the first patient cohort. Intracranial response in the other 
three cohorts was a secondary endpoint. With a median follow-up of 8.5 months, 
the intracranial response rate in the 76 patients enrolled in cohort A was 58%. The 
intracranial response rates in the 16 patients enrolled in cohort B, 16 patients enrolled 
in cohort C, and 17 patients enrolled in cohort D were 56, 44, and 59%, respectively. 
Therefore, clinical benefit intracranially was appreciated in all four cohorts even 
in patients with worsened performance status (ECOG 2) and symptomatic brain 
metastases. Longer follow-up is needed to determine effects on survival and long-
term intracranial metastases control rates.
While systemic therapies can lead to intracranial efficacy in a subset of meta-
static melanoma patients, multimodality approaches may lead to further improve-
ment in clinical outcome. A meta-analysis performed in April 2017 identified six 
retrospective studies which compared treatment with stereotactic radiotherapy 
alone to radiotherapy plus ipilimumab [31]. Of the 411 patients identified, 128 were 
treated with a combined radiotherapy and immunotherapy approach, while 283 
received radiotherapy alone. Combination therapy significantly improved survival 
(HR 0.74, p = 0.04) without significantly increasing the incidence of adverse 
events. The authors conclude that combining stereotactic radiosurgery (SRS) is safe 
and effective treatment option.
Given the survival benefits of initial immunotherapy treatment with a PD-1 
inhibitor as opposed to ipilimumab in patients with melanoma who have brain 
metastases, one may expect that SRS plus a PD-1 inhibitor may incrementally 
improve intracranial response and survival compared to treatment with SRS plus 
ipilimumab. A study of patients who received SRS plus a PD-1 inhibitor had a 
median overall survival of 20.4 months as opposed to 7.5 months in patients treated 
with SRS plus CTLA-4 blockade [32]. A single institution retrospective study 
assessed the intracranial metastasis control rate in patients treated with SRS for 
melanoma brain metastases within 3 months of receiving treatment with anti-PD-1 
immunotherapy, anti-CTLA-4 immunotherapy, BRAF plus MEK inhibitor targeted 
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therapy, anti-BRAF monotherapy, or cytotoxic chemotherapy [33]. The 12-month 
distant melanoma metastasis control rates were 38, 21, 20, 8, and 5%, respectively. 
Local melanoma brain metastasis control rates were similar among the groups. 
Combining systemic therapy with SRS was overall well tolerated without significant 
increase in neurotoxicity. Multivariate analysis showed improved overall survival in 
patients treated with immunotherapy or BRAF targeted therapy when compared to 
those treated with cytotoxic chemotherapy.
3. Conclusions
Treatment of patients with melanoma brain metastases should be based upon a 
personalized treatment plan that may include multimodality approaches utilizing 
systemic therapy, surgery, and radiation therapy. The treatment approach will be 
impacted by multiple factors including but not limited to comorbidities, perfor-
mance status, number, size, and location of brain metastases, CNS metastasis-
related symptoms, steroid needs, prior therapy, the presence or absence of a BRAF 
mutation, and patient preference. Recent advances identifying immunomodulatory 
and BRAF-targeted therapies with intracranial efficacy have led to outcomes that 
are better than historically expected through the use of anti-PD-1 monotherapy, 
combined anti-CTLA-4 plus anti-PD-1 blockade, and if patients with a V600 BRAF 
mutation combined BRAF and MEK inhibition.
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